Terug
Dagbereik
€ 9,22
€ 9,60
52-Weeksbereik
€ 5,01
€ 11,97
Volume
2.703.706
50D / 200D Gem.
€ 9,23
/
€ 7,97
Vorige Slotkoers
€ 9,26
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (631 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 3,5 | 0,2 |
| P/B | — | 3,0 |
| ROE % | — | 3,6 |
| Net Margin % | 39,2 | 3,8 |
| Rev Growth 5Y % | 54,4 | 9,9 |
| D/E | — | 0,2 |
Koersdoel Analisten
Hold
€ 14,50
+55.2%
Low: € 11,00
High: € 18,00
Forward WPA
-€ 0,36
Omzet Sch.
399,79M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 0,90
€ 0,44 – € 1,38
|
453,89M | 1 |
| FY2029 |
€ 0,33
€ 0,16 – € 0,51
|
352,52M | 1 |
| FY2028 |
€ 0,26
-€ 0,52 – € 0,97
|
350,42M | 5 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-26 | -€ 0,48 | € 0,11 | +122,7% |
| 2025-11-06 | -€ 1,08 | -€ 0,62 | +42,6% |
| 2025-08-06 | -€ 0,07 | € 0,62 | +985,7% |
| 2025-05-08 | € 0,71 | € 2,93 | +312,7% |
| 2025-02-27 | -€ 0,75 | -€ 0,51 | +32,0% |
| 2024-11-12 | -€ 0,87 | -€ 0,76 | +12,6% |
| 2024-08-08 | € 1,64 | € 0,99 | -39,6% |
| 2024-05-10 | -€ 1,04 | -€ 1,05 | -1,0% |
Dividend History
Yield
0,00%
Payout Ratio
0,00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Belangrijkste Punten
Revenue grew 54,42% annually over 5 years — strong growth
Net margin of 39,19% shows strong profitability
Negative free cash flow of -250,20M
P/E of 3,46 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 10,27%
Capital efficient — spends only 0,49% of revenue on capex
Groei
Revenue Growth (5Y)
54,42%
Revenue (1Y)64,69%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC348,97%
Net Margin39,19%
Op. Margin50,14%
Veiligheid
Debt / Equity
N/A
Current Ratio2,13
Interest Coverage24,98
Waardering
P/E Ratio
3,46
Forward P/EN/A
P/B RatioN/A
EV/EBITDA2,72
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 64,69% | Revenue Growth (3Y) | 42,10% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 54,42% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,12B | Net Income (TTM) | 440,30M |
| ROE | N/A | ROA | 37,42% |
| Gross Margin | 93,67% | Operating Margin | 50,14% |
| Net Margin | 39,19% | Free Cash Flow (TTM) | -250,20M |
| ROIC | 348,97% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2,13 |
| Interest Coverage | 24,98 | ||
| Dividends | |||
| Dividend Yield | 0,00% | Payout Ratio | 0,00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 3,46 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 1,35 |
| PEG Ratio | -0,01 | Forward PEG | N/A |
| EV/EBITDA | 2,72 | Fwd EV/EBITDA | N/A |
| Forward P/S | 3,81 | Fwd Earnings Yield | N/A |
| FCF Yield | -16,44% | ||
| Market Cap | 1,52B | Enterprise Value | 1,53B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,12B | 682,16M | 556,38M | 1,60B | 197,58M |
| Net Income | 440,30M | -187,50M | -545,06M | -657,94M | -1,74B |
| EPS (Diluted) | 2,54 | -1,23 | -5,41 | -8,42 | -23,44 |
| Gross Profit | 1,05B | 479,42M | 212,61M | 696,31M | 197,58M |
| Operating Income | 563,27M | -248,93M | -566,51M | -644,74M | -1,69B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,18B | 1,56B | 1,80B | 2,26B | 2,58B |
| Total Liabilities | 1,30B | 2,18B | 2,51B | 2,89B | 2,93B |
| Shareholders' Equity | -127,75M | -623,84M | -716,93M | -634,08M | -351,67M |
| Total Debt | 248,81M | 230,42M | 229,08M | 549,78M | 453,99M |
| Cash & Equivalents | 240,63M | 530,23M | 568,51M | 1,34B | 1,52B |
| Current Assets | 978,28M | 1,13B | 1,14B | 1,70B | 2,16B |
| Current Liabilities | 459,95M | 1,15B | 1,64B | 2,46B | 2,39B |